Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Liberty vs Pallas Health

Two GLP-1 desks, one scoreboard. We put Liberty and Pallas Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 226 · Grade C

Liberty

Visit Liberty Full brief →
vs
No. 217 · Grade C

Pallas Health

Visit Pallas Health Full brief →

The verdict

Liberty takes this head-to-head.

Liberty scores 65 to 63 on our six-factor Brief Score — Liberty (Liberty Health) is a nationwide online weight-loss and wellness service offering compounded GLP-1 sourced from FDA-registered 503B outsourcing facilities.

That doesn't make Pallas Health a bad call — it's best for readers who can absorb $597 in a single charge every 12 weeks and want a desk that will tell them who compounds and who prescribes — not readers budgeting a predictable monthly bill. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
36
50
Supply Reliability
81
82
Transparency
72
58
Access Breadth
56
66
Clinical Oversight
85
78
Track Record
73
44
LibertyBrief Score 65 · 63Pallas Health

Price, coverage & the tracker

LibertyPallas Health
Brief Score65/100 (C)63/100 (C)
SemaglutideFrom $199/mo (compounded)$199/mo average, compounded — but it bills $597 every 12 weeks, not monthly ($139 first 4 weeks)
TirzepatideFrom $299/mo (compounded)$299/mo average, compounded — but it bills $897 every 12 weeks, not monthly ($179 first 4 weeks)
CoverageCoverage not publishedNationwide — all 50 states + DC
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerNewnew to the tracker, no prior readingNewnew to the tracker, no prior reading

Liberty: New to the tracker on 1 August 2026. The published line reads From $199/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Pallas Health: First reading, 7 August 2026. The advertised averages are $199/mo semaglutide and $299/mo tirzepatide, but no month-to-month plan exists to buy: the charge is $139 up front, then $597 every 12 weeks from four weeks after approval ($179, then $897, on tirzepatide). Because an 84-day cycle recurs 4.35 times a year rather than four, those renewal terms work out at roughly $216 and $325 a month once the intro period is behind you.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.